Clinical efficacy and achievement of a complete remission in depression: Increasing interest in treatment with escitalopram;Efficacité clinique et obtention d'une rémission complète dans la dépression : intérêt de l'escitalopram

Encephale

Volumn 38, Issue 1, 2012, Pages 86-96

  Favre P ^a  

^a Hôpital Ville Evrard   (France)

Author keywords

Antidepressants; Depression; Escitalopram; Remission

Indexed keywords

AMFEBUTAMONE; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MILNACIPRAN; MIRTAZAPINE; PAROXETINE; SERTRALINE; VENLAFAXINE;

ARTICLE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; LONG TERM CARE; MAJOR DEPRESSION; MEDLINE; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SYSTEMATIC REVIEW;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; HUMANS; LONG-TERM CARE; MEDICATION ADHERENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84857782911     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.encep.2011.11.003     Document Type: Article

References (20)

1. R.J. Bielski, D. Ventura, and C.C. Chang A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder J Clin Psychiatry 65 9 2004 1190 1196
2. J.P. Boulenger Residual symptoms of depression: clinical and theoretical implications Eur Psychiatr 19 2004 209 213
3. A. Cipriani, T.A. Furukawa, and G. Salanti Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis Lancet 373 2009 746 758
4. M.E. El Mansari, O. Wiborg, and O. Mnie-Filali Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies Int J Neuropsychopharmacol 10 2007 31 40 (Pubitemid 46122750)
5. Gartlehner G, Hansen RA, Thieda P, et al. Comparative effectiveness of second-generation antidepressants in the pharmacologic treatment of adult depression. Comparative effectiveness review no. 7. Rockville, MD: Agency for healthcare research and quality, 2007. http://www.effectivehealthcare.ahrq.gov/ reports/final.cfm [Accessed Dec 19, 2008].
6. B.J. Goldstein, and P.J. Goodnick Selective serotonin reuptake inhibitors in the treatment of affective disorders, 3: tolerability, safety and pharmacoeconomics J Psychopharmacol 12 3 suppl. B 1998 S55 S87 (Pubitemid 28556670)
7. S. Kasper, D.S. Baldwin, and S. Larsson Lönn Superiority of escitalopram to paroxetine in the treatment of depression Eur Neuropsychopharmacol 19 4 2009 229 237
8. M. Kieser, and A. Szegedi Predicting stable treatment response in patients with major depression treated with hypericum extract WS 5570/5572 Pharmacopsychiatry 38 2005 194 200 (Pubitemid 41414864)
9. C.D. Kilts, A.G. Wade, and H.G. Andersen Baseline severity of depression predicts antidepressants drug response relative to escitalopram Expert Opin Pharmacother 10 6 2009 927 936
10. D.J. Kupfer Management of recurrent depression J Clin Psychiatry 52 5 suppl. 1991 28 34
11. Lieberman JA, Greenhouse J, Hamer RM, et al. Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. Neuropsychopharmacology 2005;30(3):445-60. (Pubitemid 40271148)
12. D.J. Nutt Prescribing antidepressants post-Cipriani et al J Psychopharmacol 23 8 2009 865 866
13. S. Peretti, R. Judge, and I. Hindmarch Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors Acta Psychiatr Scand Suppl 403 2000 17 25
14. G. Salanti, J.P. Higgins, and A. Ades Evaluation of networks of randomized trials Stat Methods Med Res 17 2008 279 301
15. J. Signorovitch, K. Ramakrishnan, and R. Ben-Hamadi Remission of major depressive disorder without adverse events: a comparison of escitalopram vs serotonin norepinephrine reuptake inhibitors Curr Med Res Opin 27 6 2011 1089 1096 [Epub 2011 Mar 28]
16. N. Sood, M. Treglia, and R.L. Obenchain Determinants of antidepressant treatment outcome Am J Manag Care 6 2000 1327 1336 (Pubitemid 32043656)
17. E. Szadoczky, S. Rozsa, and J. Zambori Predictors for 2-year outcome of major depressive episode J Affect Disord 83 2004 49 57 (Pubitemid 39488389)
18. L.T. Varasteh, A. Pedan, and Y. He Adherence and switching with antidepressants Value Health 10 2007 A304
19. A.G. Wade, T.E. Schlaepfer, and H.F. Andersen Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD) J Psychiatr Res 43 5 2009 568 575
20. M. Zimmerman, I. Chelminski, and M. Posternak A review of studies of the Montgomery-sberg depression rating scale in controls: implications for the definition of remission in treatment studies of depression Int Clin Psychopharmacol 19 2004 1 7 (Pubitemid 38114617)